Anticopper therapy against cancer and diseases of inflammation and fibrosis

被引：114

作者：

Brewer, GJ

机构：

[1] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 16期

关键词：

D O I：

10.1016/S1359-6446(05)03541-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Anticopper drugs that have been developed to treat Wilson's disease, a disease of copper toxicity include tetrathiomolybdate, zinc, penicillamine, and trientine. Lowering copper levels by a modest amount in non-Wilson's patients with tetrathiomolybdate inhibits angiogenesis, fibrosis and inflammation while avoiding clinical copper deficiency. Through this mechanism tetrathiomolybdate has proven effective in numerous animal models of cancer, retinopathy, fibrosis, and inflammation. Penicillamine has efficacy in rheumatoid arthritis and trientine has efficacy in diabetic neuropathy and diabetic heart disease. If clinical studies support the animal work, anticopper therapy holds promise for therapy of cancer, fibrotic disease and inflammatory and autoimmune diseases.

引用

页码：1103 / 1109

页数：7

共 50 条

[1] Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride [J].